Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 3 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
AKTUAPHARMA from Hoeilaart, company number BE0463582004, closed financial year 2025 with a result of € -115,471 after tax. Compared with financial year 2024, the result moved from € -153,447 to € -115,471. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.
€ -3.2 million
▼ € 115,471 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -115,471
▲ 25 % less loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3.2 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 13,685
▲ 3% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 355 days on average.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Profit after taxes | € -123,418 | € -153,447 | € -115,471 | ▲ € 37,976 |
| Equity | € -2,913,065 | € -3,066,511 | € -3,181,982 | ▼ € 115,471 |
| Total debts | € 2,913,065 | € 3,066,511 | € 3,181,982 | ▲ 4% |
| Retained profit | € -2,975,065 | € -3,128,511 | € -3,243,982 | ▼ € 115,471 |
Key figures of AKTUAPHARMA, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AKTUAPHARMA?
What happened at AKTUAPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 115,471. Source: NBB ↗
- Viatris GX BV stepped down as director. NBB
- DOCPHARMA BV stepped down as director. NBB
- Viatris GX BV became a director. NBB
- DOCPHARMA BV became a director. NBB
- New establishment in Hoeilaart. KBO
- Start of the company according to the CBE. KBO
In short
From € 123,418 loss in 2023 to € 115,471 loss in 2025.
Management
The shares are held by Docpharma BV (100%) and Matrix Laboratories BV (0%).
Directors
According to the 2025 annual accounts
since 2020 · until 2026
Director · represented by Tomasz BUCZEK
since 2020 · until 2026
Shareholders
Docpharma BV · holding of Viatris GX BV
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Terhulpsesteenweg 6A
1560 Hoeilaart
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0463.582.004
- VAT number
- BE 0463.582.004
- Registered office
- Terhulpsesteenweg 6A, 1560 Hoeilaart
- Names & denominations
- AKTUAPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 June 1998
- Peppol
- Active · Active since 20 Nov 2020